Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial.
Alice Bernard-TessierEmmanuelle JeannotDavid GuenatAlice DebernardiMarc MichelCharlotte ProudhonAnne Vincent-SalomonIvan BiècheJean-Yves PiergaBruno BuecherAurélia MeurisseÉric FrançoisRomain CohenMarine JaryVéronique VendrelyEmmanuelle SamalinFarid El HajbiNabil Baba-HamedChristophe BorgFrançois-Clément BidardStefano KimPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
This prospective study in advanced SCCA demonstrated a significant prognostic impact of HPV ctDNA level before first-line chemotherapy and HPV ctDNA negativity after chemotherapy completion. With a limited cost and short turnaround, this assay is a promising tool to optimize the therapeutic management of SCCA.See related commentary by Morris, p. 2030.